DBV Technologies S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DBVT research report →
Range $40 – $51
Price Chart
About the company
DBV Technologies S. A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products.
- CEO
- Daniel Tassé
- IPO
- 2014
- Employees
- 125
- HQ
- Châtillon, FR
Get TickerSpark's AI analysis on DBVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $215.77M
- P/E
- -3.25
- Fwd P/E
- 41.95
- PEG
- -0.05
- P/S
- 106.86
- P/B
- 6.02
- EV/EBITDA
- -2.21
- Div Yield
- 0.00%
- Gross Margin
- -110.70%
- Op Margin
- -3687.06%
- Net Margin
- -3631.47%
- ROE
- -121.83%
- ROIC
- -123.37%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-147,056,000
- Net Income
- $-146,947,000-29.2%
- EPS
- $-1.70-41.7%
- OCF Growth
- -16.0%
- FCF Growth
- -13.9%
- 52W High
- $26.19
- 52W Low
- $8.63
- 50D MA
- $10.56
- 200D MA
- $16.12
- Beta
- -0.21
- RSI (14)
- 38
- Avg Volume
- 352.38K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DBV said Q3 was defined by its 4-to-7-year-old BLA filing, continued manufacturing remediation work at Fareva, and early commercial build-out while cash runway extends into Q3 2027.· October 28, 2026
- DBV filed the BLA for VIASKIN Peanut Patch in children aged 4 to 7 and is now focused on FDA review readiness.
- Management said Fareva’s Warning Letter remediation is separate from the BLA review, but both converge at the pre-approval inspection stage.
- The company ended Q3 with $165.7 million in cash and cash equivalents, including $50 million of gross proceeds from ADS sales under its refreshed ATM.
- DBV said it is still targeting a toddler BLA in 2027 and is working with FDA on the sequencing so the 1-to-3 filing does not bottleneck the 4-to-7 review.
- Commercial spending is already ramping, with sales and marketing rising to $15.7 million year to date as DBV prepares for a potential launch.
DBV ended the third quarter with $165.7 million in cash and cash equivalents, including $50 million in gross proceeds from ADS sales under its refreshed ATM program. Management said this cash is expected to fund operations into the third quarter of 2027, based on a stage-gated spending plan. Year-to-date operating expenses were $166.4 million versus $107 million a year ago, an increase of $59.4 million; about half of that increase was tied to clinical and regulatory work for the BLA, while the other half reflected commercial readiness spending. Sales and marketing increased from $1.9 million to $15.7 million. The company did not provide revenue or EPS figures on the call.
Daniel Tassé framed the quarter as a major regulatory step, emphasizing the BLA submission for 4-to-7-year-olds and the company’s shift toward becoming a commercial organization. He highlighted ongoing work with Fareva on remediation after the April 2026 FDA Warning Letter, and stressed that the company wants an efficient, sequential FDA review process for the 4-to-7 and 1-to-3 filings. His tone was confident but careful, repeatedly noting that execution, inspection readiness, and regulatory coordination remain the priorities.
Virginie Boucinha said DBV finished Q3 with $165.7 million in cash and cash equivalents, which included $50 million of gross proceeds from ADS sales under the refreshed ATM. She said the updated forecast points to cash funding operations into Q3 2027, using a stage-gated investment approach tied to regulatory milestones. On the P&L, year-to-date operating expenses were $166.4 million versus $107 million last year, up $59.4 million, with roughly half spent on clinical/regulatory work and the rest on building a commercial-ready company; sales and marketing rose to $15.7 million from $1.9 million.
Analysts focused heavily on Fareva’s Warning Letter, asking whether remediation is on track, what updates are shared, and whether a reinspection has been scheduled. Management said the reinspection has not been scheduled, but they are comfortable with progress and expect sufficient buffer before the PAI; they also clarified that the Warning Letter related to a veterinary product and site-wide quality systems, not VIASKIN Peanut specifically. On the toddler program, management said COMFORT Toddlers recruitment ended in Q2, the safety readout should be largely a check-the-box update, and they want to avoid creating a review bottleneck by filing the 1-to-3 BLA too soon. Analysts also pressed on priority review, vouchers, payer discussions, and launch readiness; management said it still expects to request Priority Review for 4-to-7 based on breakthrough designation, does not expect a pediatric priority voucher to fit the product’s profile, and has already begun payer outreach and commercial infrastructure work.
The company has now filed the lead BLA, has cash into Q3 2027, and says it is building launch infrastructure in parallel with FDA review. Management sounded confident that Fareva remediation is progressing, that the PAI timing has a buffer, and that the sequential filing strategy for toddlers could help both applications move efficiently through FDA. The commercial build-out, including payer engagement and a planned 50- to 70-person sales force, suggests DBV is preparing for approval rather than merely waiting for it.
The biggest risk remains manufacturing and inspection readiness at Fareva, since the FDA Warning Letter has site-wide implications and the reinspection has not yet been scheduled. The company is also relying on a novel regulatory path for two separate BLAs, with management acknowledging that the sequencing and use of breakthrough designation across the two filings are untested. Commercially, management declined to give sales guidance, and the product still faces launch uncertainty until FDA review, PAI, and remediation are complete.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 60.8%
- Shares Outstanding
- 23.92M
- Float Shares
- 14.54M
of shares held by institutions
80 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mpm Bioimpact LLC | 3.67M | ▼ 1.55M |
| Siren, L.L.C. | 2.36M | ▲ 499.18K |
| Vivo Capital, LLC | 1.84M | 0 |
| Perceptive Advisors LLC | 1.65M | ▲ 688.96K |
| Artisan Partners Limited Partnership | 1.58M | ▲ 211.17K |
| Baker Bros. Advisors LP | 1.46M | 0 |
| Ubs Group AG | 1.44M | ▲ 121.84K |
| Patient Square Capital LP | 1.11M | ▲ 196.13K |
| Logos Global Management LP | 915.00K | ▲ 915.00K |
| Octagon Capital Advisors LP | 574.20K | 0 |
| Adar1 Capital Management, LLC | 528.29K | ▼ 484.57K |
| Ikarian Capital, LLC | 525.00K | 0 |
Held by 6 ETFs
Biggest fund positions in DBVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Mohideen Pharis | sell | 464 |
| Oct 30, 25 | Lee Philina | other | 0 |
| Jan 29, 26 | Mohideen Pharis | sell | 534 |
| Jan 12, 26 | BAKER BROS. ADVISORS LP | other | 25,005,240 |
| Jan 12, 26 | BAKER BROS. ADVISORS LP | other | 2,299,656 |
| Jan 12, 26 | BAKER BROS. ADVISORS LP | other | 25,005,240 |
| Dec 17, 25 | EPIC Bpifrance | sell | 2,036,990 |
| Dec 17, 25 | EPIC Bpifrance | sell | 40,000 |
| Dec 18, 25 | EPIC Bpifrance | sell | 1,292,103 |
| Nov 21, 25 | Mohideen Pharis | other | 253,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DBVT coverage
Recent articles, reports, and earnings notes.
No research on DBVT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DBVT report →DBV Technologies: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 18
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
marketbeat.com · Nov 9
DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds
seekingalpha.com · Nov 6
DBV Technologies to Participate in Upcoming November Investor Conferences
globenewswire.com · Nov 2
DBV Technologies S.A. (DBVT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
globenewswire.com · Oct 28
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.